NCT05966311 Pediatric Percutaneous Ultrasound Gastrostomy Technique
| NCT ID | NCT05966311 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CoapTech |
| Condition | Gastrostomy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2023-07-07 |
| Primary Completion | 2028-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2023-07-07 with a primary completion date of 2028-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to test a new device called the PUMA-G Pediatric System. The research will measure if the device works well to safely aid doctors placing gastrostomy feeding tubes in children. The PUMA-G Pediatric System is an investigational device that uses ultrasound and magnets to guide insertion of a feeding tube.
Eligibility Criteria
Inclusion Criteria: * Informed consent must be obtained from the patient or a Legally Authorized Representative (ex. parent/guardian) before any study-specific assessment is performed * Weight ≥5 (Phase 0, Phase 1, Phase 2) * Weight ≥3kg and \<10kg (Phase 3) * Estimated abdominal wall thickness ≤3cm * Indication for gastrostomy tube placement, with or without jejunal access tubing via gastrostomy tract, determined to be present for any of the following reasons: * Anatomic: Ear, nose, or throat abnormalities (Pierre-Robin sequence cleft lip palate) * Neurologic: Head trauma, Cerebral palsy * Bowel Disease: Short Bowel syndrome, intestinal dysmotility, inflammatory bowel disease, malabsorption * Failure to Thrive: Cystic Fibrosis, Cholestasis, AID, Chronic renal failure, and food refusal * Patient determined to be an appropriate candidate for PUG, PEG, or PRG by the clinical care team * Anticipated discharge \> 24 hrs following gastrostomy Exclusion Criteria: * Temperature ≥ 38 C * Systolic BP \< 80 or \> 180 mmHg * Heart Rate \< 50 or \> 160 * Estimated abdominal wall thickness \>3cm * Coagulopathy defined by INR \> 1.7 or Platelets \<50,000 * Presence of a contraindication to being in proximity to a magnet (e.g. implantable metallic device). * History of prior gastrostomy, gastrectomy (partial or complete), or abdominal trauma or upper-abdominal surgery. * Scoliosis * Atypical organ placement including microgastria * Involvement in other investigational trials within 30 days prior to screening, * Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test * Patients with HgB \< 7g/dL, or fluid resuscitated within 48hrs prior, or received blood transfusion within 48hrs prior, or active life threatening GI bleeding * Esophageal Diseases: Atresia, stricture, caustic ingestion * Spinal anomalies or atypical organ placement * Any other medical condition(s) that may put the patient at risk or influence study results in the investigator's opinion, based on the performance of a pre-procedural assessment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05966311 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 21 Years, studying Gastrostomy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05966311 currently recruiting?
Yes, NCT05966311 is actively recruiting participants. Contact the research team at jack@coaptech.com for enrollment information.
Where is the NCT05966311 trial being conducted?
This trial is being conducted at Washington D.C., United States, New York, United States, Philadelphia, United States.
Who is sponsoring the NCT05966311 clinical trial?
NCT05966311 is sponsored by CoapTech. The trial plans to enroll 80 participants.